Researchers gain new understanding of how immune cells respond to heat during fever

The study reveals that moderate fever enhances CD4 T cell activity while reducing regulatory T cell suppression, highlighting temperature’s immune effects.

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes – Biotech Investments

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Preliminary Results SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25

May 15, 2024

UQ research could lead to a more effective treatment for bladder cancer

University of Queensland research could lead to a more effective immunotherapy treatment against bladder cancer.

August 21, 2024

Curaleaf Q2 Revenue Lifts 1% Sequentially

Curaleaf Reports Second Quarter 2023 Results Second quarter 2023 revenue of $339 million, representing an increase of 4% year-over-year, and adjusted EBITDA¹ of $70 million

August 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.